Thiazolidinediones, deadly sins, surrogates, and elephants.
Cleland
John G F
JG
Department of Cardiology, Castle Hill Hospital, University of Hull, Hull HU16 5JQ, UK. j.g.cleland@hull.ac.uk
Atkin
Stephen L
SL
D002986:Clinical Trials as Topic / Q000379:methods*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000139:chemically induced* / Q000401:mortality; D012306:Risk; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone